City of Hope and Adagene launch clinical trial for advanced colorectal cancer therapy

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, and Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the launch of an innovative Phase 1 clinical trial to explore a new combination therapy for patients battling metastatic colorectal cancer, particularly for those whose disease has resisted standard treatments. 

"Colorectal cancer is the second deadliest cancer in the U.S., and current treatments don't work for everyone. We urgently need to find new options, especially for the advanced stages of this challenging disease," said principal investigator Marwan G. Fakih, M.D., a City of Hope professor in the Department of Medical Oncology & Therapeutics Research and deputy director of City of Hope Comprehensive Cancer Center. 

This year alone, an estimated 159,000 Americans will be diagnosed with colorectal cancer, and the disease will claim about 55,230 lives, according to the American Cancer Society. 

City of Hope's trial will enroll up to 36 patients to evaluate two experimental drugs, ivonescimab and muzastotug (ADG126)*, in the treatment of advanced microsatellite stable colorectal cancer. Ivonescimab activates the immune system's T cells to attack cancer cells as it cuts off the blood supply to tumors, while ADG126 enhances the immune system's ability to recognize and destroy cancer. The two drugs are expected to result in synergistic antitumor activity. 

Based on insights gleaned from past studies, we expect this powerful drug combination will result in more potent activation of the immune system within tumors, leading to potential tumor regression or death. Our mission is to speed lifesaving care to patients by crafting a more effective therapy that enhances quality of life and boosts survival rates." 

Marwan G. Fakih, M.D., Professor, Department of Medical Oncology & Therapeutics Research, City of Hope 

Physician-led innovation to reshape patient care 

Investigator-initiated trials like this one are clinical studies designed by doctors or scientists rather than an industry sponsor. Fueled by researchers' scientific curiosity, medical insight and dedication to patient-centered care, these trials provide independent, real-world data that can ignite therapeutic advances and shift clinical guidelines. 

Dr. Fakih and his colleagues will initially evaluate the combination of ivonescimab and ADG126 in patients who progressed on prior systemic therapy and will determine the most optimal dosing combination based on safety and efficacy. Once the optimal dose is identified, they plan to move this combination earlier on in the treatment of metastatic colorectal cancer. Specifically, they will explore combining this immunotherapy combination with 5-FU, the backbone of chemotherapy treatments in colorectal cancer. Subsequently, they will add an additional chemotherapy drug, irinotecan, which is commonly used in the first-line and second-line treatment of metastatic colorectal cancer. 

"We hope that the combination of immunotherapy with ivonescimab and ADG126 will work hand in hand with chemotherapy to improve further tumor shrinkage in advanced colorectal cancer," Dr. Fakih said. "The combination of ivonescimab, ADG126 and 5-FU has the potential to serve as a more effective maintenance therapy in metastatic colorectal cancer, deepening and maintaining responses to therapy. The combination of ivonescimab, ADG126, 5-FU and irinotecan has the potential to serve as a first-line treatment in metastatic colorectal cancer and improve further on the chances of remission, regression and duration of disease control." 

Peter Luo, Ph.D., chairman, CEO and president of R&D at Adagene, added, "This is the third clinical program to combine muzastotug or ADG126 with a next generation PD-1 bispecific with the goal of driving additional survival benefit for patients. This trial further validates and broadens the potential use of ADG126 as a foundational combination backbone to potentially drive more clinically meaningful survival benefits for patients. 

"ADG126 is designed to activate preferentially in the tumor microenvironment, enabling CTLA-4 blockade while limiting on-target, off-tumor activity in healthy tissues. By combining this approach with complementary immune, angiogenic and cytotoxic mechanisms, the study will assess the safety and preliminary antitumor activity of these regimens. We value City of Hope's leadership and clinical expertise in colorectal cancer." 

Fighting a high risk of recurrence 

Some 85% of colorectal cancer cases are classified as microsatellite stable (MSS), which has a higher risk of returning after treatment. Despite numerous clinical studies, no new therapies have outperformed existing treatments in halting growth. 

Recent findings, however, have suggested promising new directions, including: 

  • Integrating ivonescimab and chemotherapy significantly improved results in a small trial of 22 people, with 82% of the patients responding positively. 
  • Blending two treatments - one targeting a protein called PD-1 and another targeting blood vessel growth (VEGFR) - helped patients whose colorectal cancer had not spread to the liver. 
  • Ivonescimab targets both PD-1 and VEGF, potentially enhancing effectiveness while reducing side effects. When paired with drugs that block PD-1, ADG126 boosted the immune system's ability to combat cancer. 

Building off these discoveries, Dr. Fakih and his team developed the current trial to investigate how combining ivonescimab and ADG126 affects patients with advanced colorectal cancer. 

In integrating the approach with traditional chemotherapy, his work aims to pinpoint the safest dosage for new drug combinations and determine how long they combat cancer growth. 

"The clock is ticking; we can't afford to lose more patients to this devastating disease," Dr. Fakih said. "Our study is a crucial step forward in finding better approaches for fighting advanced colorectal cancer." 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Chronic stress promotes oral cancer through a brain–immune pathway